The Latest Breaking News from Novartis

Chinook wasn't looking to sell when Novartis approached. But the deal might be the best bet for patients — and KDNY stockholders.

Lawmakers are beginning to consider ways in which artificial intelligence systems are involved in inventive processes like discovery of new drugs, and how the use of such technologies affects what is, and is not, patentable.

Novartis stock surged Monday after the company's treatment reduced the risk of relapse in patients with early-stage breast cancer.

Swiss firm’s withdrawal from Leqvio trial with NHS dents government plans to attract post-Brexit research and investment

Dr Asha Umrawsingh, 50, was first diagnosed with breast cancer in 2010

Highlights from Fortune's dinner in Davos.

GSK stock and NVO stock rose Wednesday, though both beat forecasts. Novartis stock skidded on lighter-than-expected sales.

It's about delivering on corporate missions in a sustainable way, they said at Davos.

Pharmaceutical company Novartis (NVS) maintained its growth momentum in the third quarter of fiscal 2022, and the company’s growth prospects look promising, supported by its clear focus on five core therapeutic areas, having multiple significant in-market and pipeline assets. Given NVS’ reliable dividend payments and high profitability, this large-cap stock…